Patent · US Active

Avian influenza and fowl adenovirus type 4 bi-combined genetic engineering subunit vaccine and method for preparing the same

US11305006B2 · kind B2 · utility

0Cited by
2References
10Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 13, 2021
Grant dateApr 19, 2022
Priority date
Expiry dateSep 13, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12R2001/84
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure relates to the technical field of veterinary biological products, and discloses an avian influenza and fowl adenovirus type 4 bi-combined genetic engineering subunit vaccine. An antigen in the vaccine is a fusion antigen; the fusion antigen has a) avian influenza virus HA protein; b) fowl adenovirus fiber2 protein; c) a specific linker peptide located between the avian influenza virus HA protein and the fowl adenovirus fiber2 protein; the amino acid sequence of the specific linker peptide is as shown in SEQ ID NO:2. This vaccine contains the fusion antigen which can induce poultries to produce a high-level specific antibody to protect poultries from avian influenza and fowl adenovirus infection. Meanwhile, the disclosure also discloses a method for preparing the vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.